Recall of Various Eye Drops Due to Sterility Concerns
Areazine synthesizes this FDA recall directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
K.C. Pharmaceuticals, Inc. is recalling 182,424 bottles of various branded eye drops because of a lack of assurance of sterility, affecting products distributed nationwide in the United States.
What this FDA recall tells you, and what most readers miss
This notice was issued by FDA on April 14, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - FDA Recalls - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action, a single localized FDA recall is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (recall, product-safety, fda, Drugs) map to related alerts in the same area of risk - browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
Recall of Various Eye Drops Due to Sterility Concerns
What Happened
K.C. Pharmaceuticals, Inc. is recalling certain eye drops due to a lack of assurance of sterility, as classified by the FDA as a Class II recall.
Which Products Are Affected
The affected products include various branded sterile eye drops, specifically: a) Best Choice Eye Drops, UPC 070038470106; b) QC-Quality Choice Sterile Eye Drops Irritation Relief, NDC 83324-190-14; c) Discount Drug Mart Eye Drops A.C., UPC 093351011580; d) Good Sense Sterile Eye Drops, NDC 50804-160-01; e) Walgreens Eye Drops, UPC 311917179544; f) CAREONE Itchy Relief Eye Drops; g) Equaline Eye Drops, UPC 041163251144; h) TopCare Health Eye Drops, UPC 036800036406; i) Meijer Eye Drops, NDC 41250-598-01; and j) H.E.B A.C. Eye Drops, UPC 041220437467. All affected products have lot number AC24E01 and expiration date of 05/31/26. A total of 182,424 bottles are involved, and they were distributed nationwide in the US.
What You Should Do
Consumers who have the affected eye drops should stop using them immediately and contact the recalling firm, K.C. Pharmaceuticals, Inc., for further instructions, as this is a voluntary firm-initiated recall.
Why This Matters
This recall addresses potential risks associated with non-sterile eye drops, which could impact consumer safety by affecting eye health; it involves multiple brands and a large quantity of products distributed across the country.
Source
FDA Recall Number D-0409-2026, attributed to the FDA.
Original source: FDA Official Notice ↗
Related FDA Recalls
All FDA Recalls →Frequently Asked Questions
Common questions about this FDA recall.